📅 November is American Diabetes Month, which raises the question: Did you know that some of the most exciting innovations in this field are expected in Type 1 Diabetes Mellitus in the coming years, not Type 2?
Amid the buzz around GLP-1s, the Type 2 Diabetes market is on a remarkable growth path. Ozempic and Mounjaro are projected to add a whopping $28Bn in sales alone in the coming years, reaching ~$45Bn+ in combined sales by 2028. These drugs are making waves not only for Diabetes management but also in Obesity through off-label use.
But it’s in Type 1 Diabetes where we're seeing some of the more exciting drug innovation. Two clinical therapeutics stand out in particular:
➡️ VX-880 by Vertex Pharmaceuticals: A phase 1/2 cell therapy aimed at restoring insulin production by transplanting insulin-producing pancreatic cells, potentially reducing the need for insulin injections. The first trial participant needed 91% less insulin 90 days after receiving an infusion.
➡️ CTX-211 by CRISPR Therapeutics: A phase 1/2 gene-editing therapy designed to create immune-evasive insulin-producing cells, addressing the autoimmune nature of Type I Diabetes.
Endocrinologists are cautiously optimistic, with equity research projecting both VX-880 and CTX-211 to each reach over $500M in sales by 2030.
As these therapies advance, they hold the promise of changing the way we approach Type 1 Diabetes, potentially transforming lives and redefining what effective care looks like. Keep an eye on this space moving forward.
Comments